The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.
Roman Rouzier
Consultant or Advisory Role - Roche
Honoraria - Roche
Expert Testimony - Roche
Philippe Morice
No relevant relationships to disclose
Anne Floquet
No relevant relationships to disclose
Frédéric Selle
No relevant relationships to disclose
Eric Lambaudie
No relevant relationships to disclose
Virginie Fourchotte
No relevant relationships to disclose
Christophe Pomel
No relevant relationships to disclose
Raffaele Fauvet
No relevant relationships to disclose
Pierre Emmanuel Colombo
Consultant or Advisory Role - Roche
Elsa Kalbacher
No relevant relationships to disclose
Philippe Follana
No relevant relationships to disclose
Sandrine Martin
No relevant relationships to disclose
Anne Lesoin
No relevant relationships to disclose
Fabrice Lecuru
No relevant relationships to disclose
Patricia Pautier
No relevant relationships to disclose
Frederic Guyon
No relevant relationships to disclose
Paul H. Cottu
No relevant relationships to disclose
Florence Joly
No relevant relationships to disclose
Youssef Ghazi
Employment or Leadership Position - Roche
Elisabeth Chereau
No relevant relationships to disclose